NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference

AMES, Iowa, Dec. 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation NLNK announced today that the company will present at the 36^th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 11:00am PT / 2:00pm ET in San Francisco, CA. 

A live webcast of the conference presentation will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events & Presentations."  

About NewLink Genetics Corporation

NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.  NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer.  Indoximod is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies.  For more information, visit www.newlinkgenetics.com, and follow us on Twitter @NLNKGenetics.

###

Investor Contact:

Lisa Miller

Director of Investor Relations

NewLink Genetics

(515) 598-2555

lmiller@linkp.com

Media Contact:

Vivian Ni

Public & Media Relations

LaVoieHealthScience

617-374-8800, ext. 109

vni@lavoiehealthscience.com